News
BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...
In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and ...
Shares of steel companies soar after President Donald Trump says he will raise tariffs on imported steel to 50% from 25%.
Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the pharmaceutical company expands its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback